Review anchor
Casein kinase I isoform epsilon
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
Evidence Snapshot
Casein kinase I isoform epsilon
CHEMBL4937
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Casein kinase I isoform epsilon as ChEMBL target CHEMBL4937, mapped to UniProt P49674. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL4937
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P49674
Casein kinase I isoform epsilon
UniProt accession via ChEMBL component mapping
As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Casein kinase I isoform epsilon matters
Casein kinase I isoform epsilon is reviewed as Casein kinase I isoform epsilon (UniProt P49674); Casein kinase I isoform epsilon shows approved-linked disease relevance led by follicular lymphoma. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 10 approved drugs, 2442 compounds, and 336 assays, with lead potency reaching pChEMBL 10.0.
Protein context
Casein kinase I isoform epsilon
Casein kinase I isoform epsilon Sequence length is 416 aa.
Review this target as Casein kinase I isoform epsilon, mapped to UniProt P49674. Sequence length is 416 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P49674
Protein
Disease context
follicular lymphoma
Casein kinase I isoform epsilon shows approved-linked disease relevance led by follicular lymphoma. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include UMBRALISIB TOSYLATE.
Start review with follicular lymphoma because it currently carries approved-linked support. Linked drugs include UMBRALISIB TOSYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 10 approved drugs, 2442 compounds, and 336 assays for this target. The dominant activity type is IC50. CHEMBL5914602 is the current potency anchor at pChEMBL 10.0.
Use CHEMBL5914602 as the tractability anchor when discussing potency (pChEMBL 10.0).
Activity source · ChEMBL 36 via Core Engine
10 approved
pChEMBL 10.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Casein kinase I isoform epsilon matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P49674, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why follicular lymphoma is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
2442
Total Compounds
336
Total Assays
10
Approved Drugs
IC50: 1796.0, KI: 6.0, EC50: 7.0, KD: 399.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL5914602
|
10.0 | IC50 | — |
|
|
No preferred name
CHEMBL5948403
|
10.0 | IC50 | — |
|
|
No preferred name
CHEMBL5757040
|
9.9 | IC50 | — |
|
|
No preferred name
CHEMBL5819750
|
9.8 | IC50 | — |
|
|
No preferred name
CHEMBL5885676
|
9.7 | IC50 | — |
Approved Drugs
Source Header